Analyst Ratings For Biohaven Pharmaceutical Holding Co Ltd (NASDAQ:BHVN)
Today, William Blair reiterated its Outperform rating on Biohaven Pharmaceutical Holding Co Ltd (NASDAQ:BHVN).
There are 5 buy ratings on the stock.
The current consensus rating on Biohaven Pharmaceutical Holding Co Ltd (NASDAQ:BHVN) is Buy (Score: 3.00) with a consensus target price of $40.80 per share, a potential 23.34% upside.
Some recent analyst ratings include
- 10/3/2017-William Blair Reiterated Rating of Outperform.
- 9/12/2017-Piper Jaffray Companies Reiterated Rating of Buy.
- 5/30/2017-Barclays PLC initiated coverage with a Overweight rating.
Recent Trading Activity for Biohaven Pharmaceutical Holding Co Ltd (NASDAQ:BHVN)
Shares of Biohaven Pharmaceutical Holding Co Ltd closed the previous trading session at with shares trading hands.